RegeneRx

Proxy Materials for RegeneRx Annual Meeting - September 10, 2014

Link to document.

Shareholder letter - Thursday May 22, 2014

Link to document.

RegeneRx Pipeline

RegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company focused on tissue protection, repair and regeneration with an extensive portfolio of product candidates for first-in-class therapeutic peptides.

Latest News:

October 20, 2014
RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy


September 30, 2014
RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging


September 3, 2014
RegeneRx Receives $1 Million Pursuant to Product License and Stock Purchase Agreement


July 15, 2014
New Report: Thymosin β4 Prevents Heart Rupture & Improves Cardiac Function after Heart Attack in Mice


July 7, 2014
RegeneRx’s Strategic Partner G-treeBNT Preparing for Phase III Dry Eye Trials in Asia with RGN-259


June 23, 2014
Chinese FDA Accepts Phase 2 IND for RGN-259 for Dry Eye


June 10, 2014
RegeneRx Chairman, Dr. Allan L. Goldstein, to Speak at Major Drug Industry Conference